Differential Regulation of Type I Interferon and Epidermal Growth Factor Pathways by a Human Respirovirus Virulence Factor by Caignard, Grégory et al.
Differential Regulation of Type I Interferon and
Epidermal Growth Factor Pathways by a Human
Respirovirus Virulence Factor
Gre ´gory Caignard
1, Anastassia V. Komarova







6, Franc ¸ois Freymuth
6, Fre ´de ´ric Tangy
1*, Pierre-Olivier Vidalain
1
1Laboratoire de Ge ´nomique Virale et Vaccination, Department of Virology, Institut Pasteur, CNRS URA 3015, Paris, France, 2Laboratoire de Bacte ´riologie-Virologie,
Ho ˆpital Lariboisie `re-APHP, Paris, France, 3Unite ´ de Ge ´ne ´tique, Papillomavirus et Cancer Humain, Department of Virology, Institut Pasteur, Paris, France, 4Groupe Logiciels
et Banques de Donne ´es, Institut Pasteur, Paris, France, 5Laboratoire de Virologie, Department of Virology, Ho ˆpital Saint-Vincent de Paul, Paris, France, 6Laboratoire de
Virologie Humaine et Mole ´culaire, Department of Virology, CHU, Caen, France
Abstract
A number of paramyxoviruses are responsible for acute respiratory infections in children, elderly and immuno-compromised
individuals, resulting in airway inflammation and exacerbation of chronic diseases like asthma. To understand the molecular
pathogenesis of these infections, we searched for cellular targets of the virulence protein C of human parainfluenza virus
type 3 (hPIV3-C). We found that hPIV3-C interacts directly through its C-terminal domain with STAT1 and GRB2, whereas C
proteins from measles or Nipah viruses failed to do so. Binding to STAT1 explains the previously reported capacity of hPIV3-
C to block type I interferon signaling, but the interaction with GRB2 was unexpected. This adaptor protein bridges
Epidermal Growth Factor (EGF) receptor to MAPK/ERK pathway, a signaling cascade recently found to be involved in airway
inflammatory response. We report that either hPIV3 infection or transient expression of hPIV3-C both increase cellular
response to EGF, as assessed by Elk1 transactivation and phosphorylation levels of ERK1/2, 40S ribosomal subunit protein S6
and translation initiation factor 4E (eIF4E). Furthermore, inhibition of MAPK/ERK pathway with U0126 prevented viral protein
expression in infected cells. Altogether, our data provide molecular basis to explain the role of hPIV3-C as a virulence factor
and determinant of pathogenesis and demonstrate that Paramyxoviridae have evolved a single virulence factor to block
type I interferon signaling and to boost simultaneous cellular response to growth factors.
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Introduction
Viruses need to interact with host macromolecules to hijack the
cellular machinery and replicate. These interactions are essential
for viruses to target endocytic pathways and penetrate host cells, to
recruit cellular transcription and/or translation machinery, and to
achieve intracellular migration and viral particles assembly. But
viruses also encode virulence factors that induce a substantial
alteration of host cell functions and genetic programs to increase
virus replication and spreading. For example, specific viral factors
stimulate survival pathways to prevent apoptosis of infected cells or
inhibit cell signaling involved in immune response. Among these
pathways, IFN-a/b signaling represents a prime target for viruses
because of its critical role in the induction of both innate and
adaptive antiviral immune responses [1]. IFN-a/b transduce
signals through direct binding to a cell surface receptor composed
of two transmembrane subunits, IFNAR1 and IFNAR2c [2]. This
interaction activates IFNAR1/IFNAR2c associated kinases Tyk2
and Jak1 that subsequently phosphorylate STAT2 and STAT1
transcription factors. Activated STAT1 and STAT2, altogether
with IRF9, form the Interferon-Stimulated Gene Factor 3 that
binds IFN-stimulated response element (ISRE) promoter sequenc-
es to induce a large antiviral gene cluster. As a consequence, most
viruses that are pathogenic in vertebrates have evolved virulence
factors both to block IFN-a/b expression and signal transduction
downstream of IFN-a/b receptor.
Human parainfluenza virus type 1 (hPIV1) and human
parainfluenza virus type 3 (hPIV3) are important human pathogens
that belong to Respirovirus genus (Paramyxoviridae family; [3]). These
viruses are responsible for upper respiratory tract infections and
colds, but often spread to the lower respiratory tract causing
bronchitis, bronchiolitis and pneumonia in young children and
immuno-compromisedpatients. hPIV3 infectionis also suspectedto
exacerbate chronic airway inflammatory diseases like asthma [4].
Sendai virus and bovine parainfluenza virus type 3 (bPIV3) are
animal counterparts of hPIV1 and hPIV3 that infect mouse and
cattle, respectively. Respirovirus genome is a single-strand, negative-
sense RNA molecule that encodes six structural proteins (Mono-
negavirales order). While hemagglutinin-neuraminidase (HN) and
fusion (F) are membrane glycoproteins associated with the envelop
PLoS Pathogens | www.plospathogens.org 1 September 2009 | Volume 5 | Issue 9 | e1000587of hPIV3 particles, the nucleoprotein (N), the phosphoprotein (P)
and the viral polymerase (L) form the ribonucleocapsid complex.
The matrix protein (M) is at the interface between glycoprotein tails
and ribonucleocapsids.
The P gene of Respirovirus encodes for P but also for a panel of
accessory proteins by site-specific editing of P mRNA and usage of
overlapping open reading frames (ORFs). In all Respirovirus except
hPIV1, the co-transcriptional insertion of one G residue at an
editing motif midway of P mRNA leads to the expression of a
chimeric protein called V. The V proteins of bPIV3 and Sendai
virus bind MDA5 and suppress double-stranded RNA-stimulated
IFN-b production, thereby contributing to the virus evasion of host
immune response [5]. Surprisingly in hPIV3, multiple stop codons
localized downstream of the editing site prevent the normal
expression of a full-length V protein. As a result, P mRNA
molecules edited by the addition of one G residue encode for the
242 amino acid (AA)-long N-terminal residues of P followed by only
six additional AA (see Materials and Methods and [6]). But P
mRNA molecules edited by the addition of five G residues encode
forD, a proteinexhibitinga largeandspecificC-terminaldomainof
unknown function (Figure 1A). Besides co-transcriptional edition,
an overlapping ORF embedded in the first half of the P mRNA
allows the expression of a single C protein (hPIV3 and bPIV3) or a
nested setof four proteins called C9, C, Y1 and Y2 (Sendai virus and
hPIV1). The C proteins of Sendai virus and hPIV1 have a high
degree of sequence homology and have been studied in details.
They are involved in the regulation of viral RNA synthesis [7,8],the
inhibition of innate immune response [9] and potentially contribute
to the budding of viralparticles [10–12]. In particular, the C protein
of Sendai virus both inhibits IFN-b production [13,14] and blocks
interferon signaling downstream of IFN-a/b and IFN-c receptors
[15–17]. The C proteins of hPIV3 and bPIV3 only share ,35% of
sequence homology with the C proteins of Sendai virus and hPIV1,
but they have also been shown to target interferon expression and
signaling [5,18]. Although expression of the C protein of hPIV3
(hPIV3-C) is essential to virulence in vitro and in vivo [19] and
explains hPIV3 ability to block IFN-a/b signaling [20], host
proteins that bind hPIV3-C remain unknown.
Figure 1. hPIV3-C interacts with endogenous STAT1 and GRB2.
(A) Organization of the gene P of hPIV3 that encodes for three proteins:
P, D and C. Whereas conventional transcription and translation lead to
the expression of the phosphoprotein P, co-transcriptional insertion of
five G residues at the editing site by the virus RNA polymerase leads to
the expression of a chimeric protein called D. Insertion of one G residue
can also occur during transcription but two stop codons immediately
downstream of the editing site prevent the expression of the protein V
that is specific of Paramyxoviridae. The protein C is encoded by an
overlapping opened reading frame (ORF) embedded in P mRNA. (B and
C) HEK-293T cells were transfected with expression vectors encoding
GST alone or fused to the C proteins of measles virus (MV-C), hPIV3
(hPIV3-C), or Nipah virus (Nipah-C), and tested for the interaction with
endogenous STAT1 (B) or GRB2 (C). Total cell lysates were prepared
48 h post transfection (cell lysate; middle and lower panels), and co-
purifications of endogenous cellular proteins were assayed by pull-
down using glutathione-sepharose beads (GST pull-down; upper panel).
GST-tagged C proteins were detected by immunoblotting using anti-




Respiroviruses are important pathogens responsible for
acute respiratory tract infections associated with severe
airway inflammation in children, elderly and immuno-
compromised individuals. Their RNA genome encodes for
structural proteins that compose viral particles, but also for
virulence factors that alter cell biology to enhance virus
replication and spreading. Among them, the C protein
plays a critical role by blocking cellular response to type I
interferons, the main antiviral cytokines secreted during
virus infections. To provide molecular basis to this activity,
we found that the C protein of human parainfluenza virus
type 3 (hPIV3-C), the most frequent human Respirovirus,
interacts with STAT1, a key component of type I interferon
receptor complex. But hPIV3-C was also found to interact
with GRB2, an adaptor molecule involved in cellular
response to Epidermal Growth Factor (EGF), and to
enhance cell response to this cytokine. This pathway
increases protein translation, promotes cell survival and
contributes to airway inflammation and mucus secretion.
Thus, our findings show that hPIV3-C not only inhibits the
antiviral response but also stimulates cellular response to
EGF, which benefits virus replication and induces an
excessive inflammation of airways during infection.
hPIV3-C Impact on IFN-a/b and EGF Pathways
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two-hybrid screen and we report here the identification of STAT1
and GRB2 as direct interactors of hPIV3-C. Although binding to
STAT1 accounts for hPIV3-C ability to block IFN-a/b signaling,
the interaction with GRB2 was unexpected. This adaptor protein
bridges growth factor receptor tyrosine kinases (RTKs), like
Epidermal Growth Factor (EGF) receptor, to the mitogen-
activated protein kinase/extracellular signal-regulated kinase
(MAPK/ERK) pathway. Upon engagement by their ligands,
RTKs autophosphorylate on tyrosine residues to recruit adaptor
proteins containing phosphotyrosine binding (PTB) or Src
homology 2 (SH2) domains like GRB2 [21]. Once associated to
RTKs by its SH2 domain, GRB2 recruits the guanine nucleotide-
releasing factor son-of-sevenless (SOS) to activate Ras. Down-
stream events include MAPK/ERK kinase (MEK1/2) activation,
which in turn phosphorylates ERK1/2. Finally, phosphorylated
ERK1/2 directly or indirectly activates numerous cellular targets
including transcription factors (e.g. Elk1, SAP1, SAP2, c-Fos,
CREB, SRF) but also cellular factors that control mRNA
translation like eukaryotic initiation factor 4E (eIF4E) or small
ribosomal subunit S6 protein [22,23]. Growth factor binding to
RTKs regulates a multiplicity of cellular processes including
proliferation, differentiation and survival. In the respiratory tract,
this signaling cascade has been shown to trigger inflammation and
mucus secretion by epithelial cells [24–27], suggesting a critical
role in innate immunity [28]. However, excessive activation of this
pathway could benefit to virus replication by inhibiting IFN-a/b
signaling [29] and promoting infected cell survival [25].
Altogether, these data provided a rational to investigate the
functional impact of hPIV3-C expression on IFN-a/b vs EGF
receptor and MAPK/ERK signaling pathways.
Results
The C protein of hPIV3 interacts directly with STAT1 and
GRB2
To identify cellular targets of hPIV3-C, this viral protein was used
as bait in the yeast two-hybrid system to screen a human cDNA
library. The screen was performed at saturation with a 10-fold
coverage of the library (50.10
+6 diploids), and positive yeast colonies
growing on selective medium were analyzed by PCR and sequencing
to identify binding partners of hPIV3-C.STAT1 and GRB2 were the
main interactors of hPIV3-C identified in the screen with 5 and 150
yeastcoloniescorrespondingtothesecellularproteins,respectively.In
both cases, cDNA clones retrieved from the screen corresponded to
full-length STAT1 and GRB2 in frame with the Gal4-AD
transactivation domain. To validate these interactions in human
cells, GST-tagged hPIV3-C was expressed in HEK-293T cells and
purified with glutathion-sepharose beads. As shown in Figure 1B and
1C, endogenous STAT1 and GRB2 co-purified with hPIV3-C.
Highly divergent C proteins from measles virus (MV-C) and Nipah
virus (Nipah-C) failed to do so, thereby demonstrating the specificity
of identified interactions. Binding to STAT1 provides molecular basis
to the inhibition of IFN-a/b signaling by hPIV3-C [18], and parallels
the interaction previously identified between Sendai virus C protein
and mouse STAT1 [15]. Altogether, this suggests that STAT1 is a
specific cellular interactor of Respirovirus C proteins. In contrast,
binding to GRB2 is unexpected and suggests a new function for
hPIV3-C that we decided to investigate.
hPIV3-C has opposite effects on IFN-a/b and EGF
signaling pathways
The adaptor protein GRB2 plays a critical role in coupling
signal from growth factor receptors to MAPK/ERK signaling
pathway. To address the question of hPIV3-C interference with
this pathway, we used a trans-reporter gene assay that measures
Elk1 activation by ERK1/2. In this system, Elk1 transcription
factor is fused to the DNA binding domain of Gal4 (Gal4-DB) and
binds the promoter sequence of a luciferase reporter gene. Upon
stimulation with a growth factor like EGF, Elk1 is activated as
assessed by a significant increase in luciferase expression.
Surprisingly, we observed a 6-fold enhancement in this cellular
response to EGF when 36FLAG-tagged hPIV3-C was expressed
in HEK-293T cells (Figure 2A). Same results were obtained when
using hPIV3-C without a tag (14-fold enhancement) or tagged
with the red fluorescent protein Cherry (7-fold enhancement). In
contrast to hPIV3-C, neither MV-C nor Nipah-C enhanced Elk1
activity upon EGF stimulation (Figure 2A) whereas expression
levels of hPIV3-C, MV-C and Nipah-C were similar in this system
(Figure 2F, left panel). Elk1 activity was also enhanced by hPIV3-
C expression in Vero and Hela cells as well as BEAS-2B and
A549, two epithelial cell lines that originate from the respiratory
tract, which is the tissue targeted by hPIV3 in vivo (Table 1). The
effect of hPIV3-C in these different cell lines was highly significant
(see p-values in Table 1) although relatively modest when
compared to HEK-293T cells. This is probably because our
reporter system requires the co-transfection of four plasmids and
Vero, Hela, BEAS-2B and A549 cells are more difficult to
transfect than HEK-293T. In parallel experiments, cellular
response to IFN-a/b was monitored using a cis-reporter gene, of
which expression is controlled by five ISREs. As previously
reported [18], we found that hPIV3-C efficiently blocked IFN-a/b
signaling (Figure 2B) as opposed to what we observed for the EGF
pathway. Again, MV-C or Nipah-C was unable to do so.
Altogether, these results show that hPIV3-C enhances the cellular
response to EGF in addition to its ability to block IFN-a/b
signaling.
We also determined if similar effects on the EGF pathway were
observed in infected cells. HEK-293T cells were infected with
hPIV3 (MOI=3) and then transfected with Elk1 activity reporter
plasmids. Infection of HEK-293T cells was confirmed by anti-
hPIV3 hemagglutinin-neuraminidase (hPIV3-HN) immunostain-
ing and flow cytometry analysis (Figure 2E). Like hPIV3-C alone,
hPIV3 infection enhanced Elk1 activity upon EGF stimulation
(Figure 2C). Interestingly, hPIV3 infection induced a significant
level of Elk1 activity in the absence of EGF stimulation. This
suggests that in addition to hPIV3-C interaction with GRB2, other
mechanisms modulate MAPK/ERK pathway during hPIV3
infection.
Finally, to demonstrate that enhancement of Elk1 activation by
hPIV3-C is completely dependent on ERK1/2 activation, HEK-
293T cells were pre-treated with MEK1/2 inhibitor U0126 before
stimulation with EGF. This molecule targets MEK1/2 and totally
abrogates downstream phosphorylation and activation of ERK1/2
[30]. As shown in Figure 2D, Elk1 activation was blocked by
U0126, whereas hPIV3-C expression was maintained (Figure 2F,
right panel). This demonstrates that hPIV3-C is acting through
ERK1/2 stimulation. Altogether, these results support a model
where hPIV3-C interaction with GRB2 enhances cellular response
to growth factors as assessed by an increased activation of MAPK/
ERK pathway.
Phosphorylation of ERK1/2, eIF4E and small ribosomal
subunit S6 protein are stimulated by hPIV3-C expression
or hPIV3 infection
Tofurtherdocument hPIV3-C impact onMAPK/ERKsignaling
pathway, we compared the kinetic of ERK1/2 phosphorylation in
HEK-293T cells expressing hPIV3-C or not. Cells were transfected
hPIV3-C Impact on IFN-a/b and EGF Pathways
PLoS Pathogens | www.plospathogens.org 3 September 2009 | Volume 5 | Issue 9 | e1000587Figure 2. Enhanced activation of MAPK/ERK pathway and inhibition of IFN-a/b signaling by hPIV3-C. (A) HEK-293T cells were transfected
with pFA2-Elk1 to express Elk1 transcription factor fused to the DNA binding domain of Gal4, pGal4-UAS-Luc that contains the firefly luciferase
reporter gene downstream of a promoter sequence containing Gal4 binding site, and pRL-CMV that drives Renilla luciferase expression constitutively.
In addition to these three plasmids, cells were co-transfected with an expression vector encoding 36FLAG-tagged MV-C, hPIV3-C or Nipah-C or the
corresponding empty vector pCI-neo-36FLAG. 12 h after transfection, cells were starved and 6 h later EGF was added at a final concentration of
100 ng/ml. After 24 h, relative luciferase activity was determined. (B) HEK-293T cells were transfected with pISRE-Luc, a plasmid containing a
luciferase gene of which expression is controlled by five ISREs, and pRL-CMV. In addition to these two plasmids, cells were co-transfected with an
expression plasmid encoding 36FLAG-tagged MV-C, hPIV3-C or Nipah-C or the corresponding empty vector pCI-neo-36FLAG. 24 h after transfection,
1000 IU/ml of recombinant IFN-b were added. After 24 h, relative luciferase activity was determined. (C) HEK-293T cells were infected with hPIV3
(MOI=3) and then transfected with pFA2-Elk1, pGal4-UAS-Luc, pRL-CMV vectors. 12 h later, cells were starved during 6 h and stimulated with EGF at
a final concentration of 100 ng/ml. After 24 h, relative luciferase activity was determined. (D) Same experiment as (A) but 20 mM of MEK1/2 specific
inhibitor U0126 was added as indicated. (A–D) All experiments were achieved in triplicate, and data represent means6SD. (E) HEK-293T cells were
infected as in (C), and hPIV3-HN expression determined by immunostaining and flow cytometry analysis. (F) HEK-293T cells were transfected to
express 36FLAG-tagged MV-C, hPIV3-C or Nipah-C as described in (A) and (B), and relative expression levels were determined 36 h later by western
blot analysis (left panel). In a parallel experiment, HEK-293T cells were transfected to express hPIV3-C and were cultured with or without EGF in the
presence or absence of U0126 as described in (D). hPIV3-C expression level was determined by western blot analysis (right panel).
doi:10.1371/journal.ppat.1000587.g002
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transfection,theywerestarved beforestimulationwith EGF.ERK1/
2 phosphorylation was determined at 10, 30 and 120 min after
stimulation. As illustrated by one representative experiment in
Figure 3A, EGF stimulation induced ERK1/2 phosphorylation in
control cells but signal was markedly and reproducibly increased by
hPIV3-C expression at maximum phosphorylation timepoint (1.4to
2.8 fold increase; p=0.005;n=4).
We then determined the phosphorylation level of two
downstream targets of this pathway that are involved in the
control of mRNA translation, the translation initiation factor
eIF4E and the ribosomal protein S6 (Figure 3B). Before EGF
stimulation, low levels of phosphorylated eIF4E and S6 were
detectable in mock-treated cells (Figure 3B and 3D). hPIV3-C
expression had virtually no effects on this background. Thus,
eIF4E and S6 phosphorylation levels were determined at different
time-points after EGF stimulation. Because ERK1/2 activation
precedes eIF4E and S6 phosphorylation, maximal phosphoryla-
tion occurs at later time points and was determined at 30 min, 2 h,
6 h and 24 h after stimulation. As observed for ERK1/2,
phosphorylation levels of eIF4E and S6 were enhanced by
hPIV3-C expression when stimulating the cells with EGF.
To validate these observations in infected cells, HEK-293T cells
were infected with hPIV3 (MOI=3) and 24 h later, cells were
starved for 12 h before stimulation with EGF. Like hPIV3-C
expression alone, hPIV3 infection enhanced ERK1/2 phosphor-
ylation at the peak of induction, i.e. 10 min after adding EGF to
the cells (Figure 3C). Interestingly, hPIV3 infection of A549 cells
also enhanced ERK1/2 phosphorylation but the induction profile
was different. Indeed, ERK1/2 phosphorylation was not signifi-
cantly increased at the peak of induction, but the signal was
boosted by hPIV3 infection at late time points (Figure S1). The
same profile was observed when eIF4E and S6 phosphorylation
levels were analyzed in infected HEK-293T cells. hPIV3 infection
sustained the phosphorylation of these two translation factors at
late time points, but showed no increase at the peak of stimulation,
i.e. 30 min after adding EGF to the cells (Figure 3D). This could
relate to the fact that hPIV3 infection also induces low levels of
eIF4E and S6 phosphorylation in the absence of EGF stimulation
(Figure 3D). This is reminiscent to what was observed for Elk1
(Figure 2C), and suggests that hPIV3 infection induces a basal
activation of MAPK/ERK pathway leading to the constitutive
phosphorylation of downstream targets.
Altogether, these data demonstrate that hPIV3 infection or
hPIV3-C expression alone both enhance MAPK/ERK pathway
activation in EGF-stimulated cells. Several RNA viruses require an
activated MAPK/ERK pathway to produce viral components and
replicate properly (for review see [31]). To test if the same was true
for hPIV3, cells were treated for 2 h with MAPK/ERK pathway
inhibitor U0126 and infected with hPIV3 (MOI=1). Two days
after infection, cell surface expression of hPIV3-HN was detected
by immunostaining and flow cytometry. U0126 completely
blocked the expression of hPIV3-HN in hPIV3-infected cells
(Figure 4), whereas the same inhibitor had no effect when cells
were infected with MV (Figure S2). Altogether, this demonstrates
that MAPK/ERK signaling is essential for the expression of
hPIV3 proteins and suggests that hPIV3 manipulates this pathway
to increase replication efficiency.
The C-terminal region of hPIV3-C binds STAT1 and GRB2
To better understand how hPIV3-C targets both the IFN-a/b
and EGF signaling pathways, we characterized the functional
domains of hPIV3-C that bind STAT1 and GRB2. To do so, we
generated by PCR a full matrix of hPIV3-C overlapping fragments
and tested their ability to interact with either STAT1 or GRB2 in
the yeast two-hybrid system (Figure 5 and 6). Both forward and
reverse primers were designed every 75 nucleotides along hPIV3-
C sequence and fused to appropriate tails to allow gap-repair
recombination with linearized Gal4-DB yeast two-hybrid vector
(Figure 5A). All possible combinations of forward and reverse
primers were used to amplify hPIV3-C fragments. Finally,
corresponding PCR products were transformed in a yeast strain
expressing Gal4-AD fused to either STAT1 or GRB2, and growth
on selective medium was used to detect potential interactions. A
124 (AA)-long peptide encompassing position 76 to 199 located in
the C-terminal half of hPIV3-C was sufficient to bind STAT1
(Figure 5B) or GRB2 (Figure 6A). In an iterative process, we then
generated a second, a third and a fourth set of hPIV3-C fragments
corresponding to one-by-one AA deletions (Figure 5C–E and
Figure 6B–D), allowing to further reduce the STAT1 and GRB2
binding motifs to minimal peptides. A 106 AA peptide
encompassing residues 90 to 195 of hPIV3-C was sufficient to
observe the interaction with STAT1 (Figure 5E). The binding
region to GRB2 was virtually the same, encompassing AA 97 to
195 (Figure 6D).
The C-terminal region of hPIV3-C required to bind STAT1
and GRB2 in the yeast two-hybrid system is highly conserved
among Respiroviruses (Figure 7A) and suspected to fold into a
structured coiled-coil domain [18]. Furthermore, virtually the
same C-terminal region of Sendai virus C protein (AA 85-204) was
previously reported to mediate the interaction with mouse STAT1
[32]. To further validate our observations performed in the yeast
two-hybrid system, we retested by co-affinity purification the
ability of hPIV3-C fragment encompassing AA 90-195 (hPIV3-
C90-195) to interact with STAT1 and GRB2 in HEK-293T cells.
GST-tagged hPIV3-C90-195 was expressed together with 36-
FLAG-tagged STAT1 or GRB2, and purified with glutathion-
sepharose beads. Full-length hPIV3-C and the N-terminal region
encompassing AA 1-89 (hPIV3-C1-89) were used as positive and
negative controls, respectively. As shown in Figure 7B and 7C,
hPIV3-C90-195 interacted with STAT1 and GRB2, whereas
hPIV3-C1-89 did not. Although hPIV3-C90-195 interacted with
GRB2 as efficiently as full-length hPIV3-C (Figure 7C), interaction
with STAT1 was weaker suggesting that more residues contribute
to the stabilization of this interaction (Figure 7B). Altogether, these
results confirm that AA 90-195 of hPIV-3 include both STAT1
and GRB2 binding sites.
Table 1. hPIV3-C protein expression increases EGF signaling.
none MV-C hPIV3-C Nipah-C
HEK-293T 1 1.160.2 6.360.2 (p=0.0005) 1.460.2
Hela 1 1.160.02 2.460.07 (p=3.10
25) 1.260.01
Vero 1 0.960.03 2.260.02 (p=0.0002) 0.860.06
A549 1 ND 2.260.3 (p=0.005) ND
BEAS-2B 1 ND 2.760.8 (p=0.02) ND
As described in Figure 2, HEK-293T, Hela, Vero, A549 or BEAS-2B cells were
transfected with pFA2-Elk1, pGal4-UAS-Luc, pRL-CMV to measure the activation
level of MAPK/ERK signaling pathway. Cells were co-transfected with plasmids
encoding 36FLAG-tagged MV-C, hPIV3-C or Nipah-C or the corresponding
empty vector pCI-neo-36FLAG. 12 h after transfection, cells were starved and
stimulated 6 h later with 100 ng/ml of EGF. After 24 h, expression of luciferase
was quantified. Results were normalized so that reporter activity in cells
transfected with a control vector equals 1. Experiments were performed in
triplicates and data represent means6SD.
doi:10.1371/journal.ppat.1000587.t001
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PLoS Pathogens | www.plospathogens.org 5 September 2009 | Volume 5 | Issue 9 | e1000587Figure 3. Stimulation of ERK1/2, eIF4E and S6 phosphorylations by hPIV3-C expression or hPIV3 infection. (A, B, C and D) HEK-293T
cells were either transfected with an expression vector encoding 36FLAG-tagged hPIV3-C (A, B) or infected with hPIV3 (MOI=3) (C, D). After 24 h,
cells were starved for 12 h, and then stimulated with 100 ng/ml of EGF. Phosphorylation of ERK1/2 was measured at 10 min, 30 min and 2 h (A and
C) whereas phosphorylation of eIF4E on Ser209 and S6 phosphorylation on Ser235/236 were determined at 30 min, 2 h, 6 h and 24 h after EGF
stimulation (B and D). Relative phosphorylation levels of ERK1/2, eIF4E and S6 were obtained by densitometric analysis of the gels (right panels).
Expression of 36FLAG-tagged hPIV3-C in transfected cells was detected by anti-36FLAG immunoblotting (B), whereas hPIV3 infection was confirmed
by anti-hPIV3 hemagglutinin-neuraminidase (hPIV3-HN) immunoblotting (D).
doi:10.1371/journal.ppat.1000587.g003
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hPIV3-C as demonstrated above, it remained unclear whether these
interactions are mutually exclusive. To answer this question, a
competition experiment was designed where GST-tagged hPIV3-C
was co-expressed with STAT1 in the presence or absence of GRB2
(Figure 7D). In this setting, GRB2 expression prevents STAT1 co-
purification together with GST-tagged hPIV3-C. This validates our
finding that STAT1 and GRB2 interact with the same region of
hPIV3-C, and demonstrates that STAT1 and GRB2 compete for
hPIV3-C binding. Interestingly, GRB2 interaction with hPIV3-C was
not affected by STAT1 expression (Figure 7D and data not shown),
suggesting that GRB2 has a higher affinity for hPIV3-C than STAT1.
Both the N- and C-terminal domains of hPIV3-C are
required for its activity
We finally tested if hPIV3-C90-195 was able, like full-length
hPIV3-C, to block IFN-a/b signaling and enhance cellular
response to EGF stimulation. First, cells were transfected with
36FLAG-tagged hPIV3-C, hPIV3-C90-195 or hPIV3-C1-89 togeth-
er with the IFN-a/b reporter plasmid, and stimulated 24 h later
with recombinant IFN-b. Reporter gene expression was deter-
mined 24 h post transfection and found to be inhibited exclusively
by full-length hPIV3-C (Figure 8A). Although this may reflect the
weakness of hPIV3-C interaction with STAT1 (Figure 7B), this
also indicates that both the N-terminal and C-terminal regions of
hPIV3-C are required to block IFN-a/b signaling, even if only the
C-terminal region is required for the binding to STAT1. The same
constructs were tested using the Elk1 activity reporter plasmids
(Figure 8B). Again, only full-length hPIV3-C was able to enhance
Elk1 activation upon EGF stimulation whereas full-length hPIV3-
C and hPIV3-C90-195 were expressed at similar levels in
transfected cells (Figure 8B, upper right panel).
Because GRB2 binding to hPIV3-C and hPIV3-C90-195 were
essentially equivalent in co-affinity purification experiments, we
hypothesized that the N-terminal region of hPIV3-C was required
for its proper subcellular localization. Thus, hPIV3-C, hPIV3-C90-
195 and hPIV3-C1-89 were expressed in fusion downstream of the
red fluorescent protein Cherry. As shown in Figure 8C, Cherry
alone or fused to hPIV3-C90-195 localized both in the nucleus and
the cytoplasm of transfected cells. In contrast, full-length hPIV3-C
essentially accumulated at the cellular membrane whereas hPIV3-
C1-89 was in the nucleus. Although we have no explanation for this
unexpected localization of hPIV3-C1-89, these observations show
that only full-length hPIV3-C is able to target the cellular
membrane where both IFN-a/b and EGF signaling are triggered.
Discussion
Paramyxoviridae have evolved various mechanisms to block IFN-
a/b response, in particular signaling downstream IFNAR1/
IFNAR2c receptor [20,33]. Although members of Pneumovirinae
subfamily have specific genes to encode inhibitors of IFN-a/b
signaling pathway, those expressed by other Paramyxoviridae (i.e.
Paramyxovirinae subfamily) are encoded by overlapping reading
frames embedded within the gene P. Rubulaviruses express V
proteins that target STAT1 and/or STAT2 for ubiquitination and
degradation, while Morbilliviruses and Henipaviruses V proteins
essentially impair STAT1/2 phosphorylation, activation and
nuclear translocation. In addition, Morbilliviruses and Henipaviruses
also encode for C proteins of which role in the inhibition of IFN-
a/b response has been a matter of debates [34–37]. Recent
reports showed that Morbillivirus C proteins only have a minor role
in the inhibition of IFN-a/b signaling [37], but are essential to
block IFN-a/b induction [38]. Whether Henipavirus C proteins can
directly block IFN-a/b or promote viral replication through
alternative mechanisms is unclear [35]. In contrast, it has been
clearly established that Respirovirus C proteins are potent inhibitors
of IFN-a/b signaling [5,18,39–41]. In this report, we show that
hPIV3-C, but not MV-C or Nipah-C, directly interacts with
STAT1 and efficiently inhibits IFN-a/b signaling. In addition, we
identified a minimal STAT1 binding domain that encompasses
Figure 4. MEK1/2 inhibitor U0126 inhibits hPIV3 protein
synthesis in infected cells. (A, B and C) HEK-293T cells were left
untreated (A and B) or treated with 20 mM of U0126 (C) for 2 h. (B and
C) cells were infected with hPIV3 (MOI=1) and maintained in absence
(B) or presence of U0126 (C). 48 h later, expression of hPIV3-HN was
quantified by immunostaining and flow cytometry analysis. Isotypic
control (grey shadow) and hPIV3-HN expression (thick line) are shown
for each experiment.
doi:10.1371/journal.ppat.1000587.g004
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coil. Interestingly, this conserved domain is localized within the
STAT1 binding region shared by all four isoforms of Sendai virus
C protein [32]. Together, these results confirm the capacity of
hPIV3-C to block IFN-a/b signaling pathway [18], provide
molecular basis to this inhibition and clarify the fact that
Respirovirus C proteins are functionally distinct from Morbillivirus
and Henipavirus C proteins.
In addition to STAT1, we show that hPIV3-C interacts directly
with GRB2 and enhances MAPK/ERK signaling downstream of
EGF receptor (EGFR). Our data give the first example of a
Paramyxoviridae protein that contributes to the stimulation of EGFR
and MAPK/ERK pathway and provides molecular basis to this
activity. This pathway has been known for decades as a prime
target of DNA tumor viruses and oncogenic retroviruses, and its
activation represents an essential step toward carcinogenesis
[3,42]. But recent data demonstrate that non-oncogenic RNA
viruses also activate this signaling cascade to support viral
replication and spreading [31]. Whether it is activated upon
EGFR engagement or other means, MAPK/ERK pathway
Figure 5. Systematic deletion-based mapping of a minimal hPIV3-C region interacting with STAT1. (A) Fragments of hPIV3-C were
generated by PCR using a matrix combination of specific primers (left panel), and introduced into Gal4-DB vector by gap-repair in yeast cells
expressing STAT1 fused to Gal4-AD (right panel). Yeast cells were grown on selective medium lacking histidine and supplemented with 10 mM of 3-
amino-triazole (3-AT) to test the interaction-dependent transactivation of HIS3 reporter gene. Vertical and horizontal axes indicate first and last AA
residues of each fragment tested, respectively. (B), (C), (D) and (E) correspond to four iterations of this process. (E) The fourth led to the identification
of a 106 AA encompassing position 90 to 195 of hPIV3-C as the minimal STAT1 binding domain.
doi:10.1371/journal.ppat.1000587.g005
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differentiation, development, cell survival and inflammation. As a
consequence, how the activation of MAPK/ERK pathway
promotes viral replication is a complex question. Interestingly,
two non-oncogenic RNA viruses associated with acute respiratory
tract infections have been recently reported to modulate the
EGFR pathway. Both human respiratory syncytial virus (hRSV), a
member of Paramyxoviridae like hPIV3, and a rhinovirus that
belongs to Picornaviridae family activate EGFR and MAPK/ERK
pathway [25,27]. Infection of epithelial cells by these viruses
stimulates the processing and activation of EGFR ligands by
membrane matrix metalloproteinase and subsequent engagement
of EGFR through autocrine/paracrine mechanisms. Experiments
performed on rhinovirus show that viral replication and TLR3
engagement by viral RNA are both required to activate the EGFR
and MAPK/ERK pathway [27]. In this report, we show that
hPIV3 infection also activates MAPK/ERK pathway in the
absence of external stimuli, a phenomenon that possibly relies on
the engagement of pathogen recognition receptors. Although
hPIV3-C alone is unable to activate this pathway, our data suggest
that expression of this virulence factor enhances MAPK/ERK
activation above normal level in infected cells, thereby contribut-
ing to viral replication and pathogenesis.
Induction of MAPK/ERK pathway by RNA viruses has
numerous consequences on cell biology. First, it results in
increased expression of inflammatory factors, in particular
cytokines and chemokines that recruit cellular effectors of
immunity [27,43–47]. MAPK/ERK pathway was also reported
to block the antiviral response induced by IFN-a/b, making its
activation beneficial to virus replication [29]. Another conse-
quence of MAPK/ERK pathway activation is the induction of
mucin production by infected epithelial cells [24,27]. Although
mucin expression is a critical innate defense system, excessive
production of mucus results in the obstruction of airways and
delays the elimination of pathogens. Finally, it has been
demonstrated in vitro that upon hRSV infection, activation of
EGFR and MAPK/ERK pathway sustains viral replication by
retarding the death of infected cells [25]. Altogether, these data
suggest that although a moderate activation of MAPK/ERK
pathway contributes to the innate response against viruses, an
excessive activation leads to deleterious inflammation, inhibition of
IFN-a/b response, airway obstruction and infected cell survival
Figure 6. Identification of a minimal hPIV3-C region interacting with GRB2. Fragments of hPIV3-C were generated and tested for their
ability to interact with GRB2 following the procedure described in Figure 5A. (A) The first iteration identified a GRB2 binding region of 124 AA. After
two (B), three (C) and four additional rounds (D), this domain was finally reduced to a minimal GRB2 binding motif of 99 AA. This binding domain,
encompassing position 97 to 195, is contained in the STAT1 binding region of hPIV3-C previously identified in Figure 5.
doi:10.1371/journal.ppat.1000587.g006
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interaction with GRB2 and EGFR pathway participates in such
deregulation of airway epithelium homeostasis to promote hPIV3
replication and spreading. A consequence of such perturbations
could be an aggravation of chronic inflammatory airway diseases
like asthma or chronic obstructive pulmonary disease as already
suggested by epidemiological links with Paramyxoviridae infections
and in vivo models [48,49].
Besides its effects on immune response, activation of MAPK/
ERK pathway has direct consequences on viral replication as
assessed by in vitro experiments. It is now well documented that
MAPK/ERK pathway inhibition with U0126 or PD098059
deeply impairs the replication of numerous RNA viruses including
hRSV ([50]; and for review see [31]). Similarly, we show in this
report that MAPK/ERK pathway inhibition prevents hPIV3
protein expression in infected cells as assessed by hPIV3-HN
detection. In influenza virus infected cells, membrane accumula-
tion of influenza virus hemagglutinin (HA) induces lipid-rafts
clustering that leads to MAPK/ERK pathway activation and
nuclear export of viral ribonucleoprotein complexes to achieve
Figure 7. STAT1 and GRB2 bind to the same region of hPIV3-C. (A) The C proteins of Respiroviruses are highly conserved at their C-terminus.
Sequences from Sendai virus (NC_001552), human parainfluenza virus type I (hPIV1; NC_003461), bovine parainfluenza virus type 3 (bPIV3;
NC_002161) and hPIV3 (EU719627.1) were aligned with CLC Workbench 4.0.1. Identical residues are highlighted by black boxes. (B and C) Full-length
hPIV3-C, N-terminal region hPIV3-C1-89 and C-terminal region hPIV3-C90-195 were tested for their ability to interact with STAT1 or GRB2. HEK-293T cells
were transfected to co-express GST fused to full-length hPIV3-C or fragments and 36FLAG-tagged STAT1 (B) or GRB2 (C). Total cell lysates were
prepared 48 h post transfection (cell lysate; middle and lower panels), and co-purifications of 36-FLAG-tagged proteins was assayed by GST pull-
down (upper panel). Tagged proteins were detected by immunoblotting using anti-GST or anti-36FLAG antibodies. (D) GRB2 and STAT1 compete for
hPIV3-C binding. GST alone (line 1) or GST-tagged hPIV3-C (line 2–6; 300 ng/well in a 6-well plate) were expressed in HEK-293T cells together with
600 ng/well (line 3–4; ‘‘++’’) or 150 ng/well (line 5–6; ‘‘+’’) of 36-FLAG-tagged STAT1 and/or 36-FLAG-tagged GRB2 (line 2, 3 and 5; 600 ng/well). Total
cell lysates were prepared 48 h post transfection (cell lysate; middle and lower panels), and co-purification of 36-FLAG-tagged proteins was assayed
by GST pull-down (upper panel).
doi:10.1371/journal.ppat.1000587.g007
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PLoS Pathogens | www.plospathogens.org 10 September 2009 | Volume 5 | Issue 9 | e1000587Figure 8. Full-length hPIV3-C is required to modulate IFN-a/b and EGF signaling. (A and B) hPIV3-C90-195 and hPIV3-C1-89 were tested for
their ability to modulate IFN-a/b or EGF signaling. (A) As described in Figure 2, HEK-293T cells were transfected with pISRE-Luc and pRL-CMV to
determine the activation level of IFN-a/b signaling pathway. Cells were co-transfected with expression plasmids encoding 36FLAG-tagged full-length
hPIV3-C (CFL) or fragments. 24 h after transfection, 1000 IU/ml of recombinant IFN-b were added. After 24 h, relative luciferase activity was
determined. Experiments were performed in triplicates, and data represent means6SD. (B) As described in Figure 2, cells were transfected with pFA2-
Elk1, pGal4-UAS-Luc and pRL-CMV to determine the activation level of MAPK/ERK signaling pathway. Cells were co-transfected with expression
plasmids encoding full-length hPIV3-C (CFL) or fragments. 12 h later, cells were starved during 6 h and stimulated with EGF at a final concentration of
100 ng/ml. After 24 h, relative luciferase activity was determined. Experiments were performed in triplicate, and data represent means6SD. As a
control, relative expression levels of CFL,C 90-195 and C1-89 were determined by western blot analysis (upper right panel). (C) Full-length hPIV3-C, hPIV3-
C90-195 or hPIV3-C1-89 was expressed in fusion downstream of the red fluorescent protein Cherry to determine subcellular localization in HEK-293T
cells. 24 h after transfection, cells were fixed with PFA, permeabilized and labeled with DAPI to stain nuclei. Single confocal sections show Cherry-
tagged protein fluorescence in red and DAPI staining in blue.
doi:10.1371/journal.ppat.1000587.g008
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is only cytoplasmic, mechanisms involved are necessarily distinct.
A possible link between MAPK/ERK pathway and hPIV3 protein
expression lies in the fact that among downstream targets of this
pathway are essential factors of cellular translational machinery.
We show that hPIV3-C expression enhances the phosphoryla-
tion of S6 and eIF4E. The small ribosomal subunit protein S6 is
the major phosphoprotein of eukaryotic ribosomes with five
phosphorylation sites (Ser235, Ser236, Ser240, Ser244, and
Ser247). Two families of serine/threonine kinases phosphorylate
S6 in vitro: S6K1/2 and p90 ribosomal S6 kinase (RSK). Recently
it has been shown that MAPK/ERK signaling pathway activates
RSK family members that contribute to S6 phosphorylation on
Ser235/236 thereby stimulating cap-dependent translation [23].
In addition, eIF4E that interacts with the cap structure and brings
translation initiation factors together with the small ribosomal
subunit via the scaffold protein eIF4G, undergoes regulated
phosphorylation on Ser209 upon MAPK/ERK pathway activa-
tion. This phosphorylation event is dependent on eIF4G-
associated MAPK signal-integrating kinases, Mnk1 and Mnk2
[22]. eIF4E is believed to be the least abundant of all initiation
factors and therefore considered as a perfect target to regulate
protein synthesis. Even though there is no direct link between
eIF4E phosphorylation and the enhanced translation observed, the
fraction of phosphorylated eIF4E dramatically increases following
treatment of the cells with growth factors, hormones and mitogens.
Therefore, eIF4E phosphorylation has been associated with
increased translation rates. hPIV3 mRNAs are capped and
polyadenylated like their host counterparts. Thus, S6 and eIF4E
phosphorylation together with a high level of viral gene
transcription may contribute to a rapid switch toward viral protein
synthesis within infected cells.
Specific biochemical investigations are still required to decipher
how hPIV3-C can both inhibit IFN-a/b signaling and enhance
EGFR and MAPK/ERK pathway. When searching the literature
for viral proteins that target GRB2, we found specific reports on
NS5A from hepatitis C virus and ORF3 from hepatitis E virus
[54,55]. Although NS5A inhibits MAPK/ERK activation induced
by exogenous EGF, ORF3 was described as an activator of
MAPK/ERK pathway like hPIV3-C. Both NS5A and ORF3
exhibit a proline-rich motif (PXXP) to bind the Src homology 3
(SH3) domains of GRB2, but there is no such motif in hPIV3-C
suggesting that other mechanisms mediate STAT1 and GRB2
binding. Interestingly, these two cellular proteins exhibit SH2
domains. Such domains typically bind a phosphorylated tyrosine
residue in the context of a longer peptide motif within a target
protein. Although there is no evidence that hPIV3-C becomes
phosphorylated, we have tested hPIV3-C interaction with mutant
STAT1 and GRB2 exhibiting SH2 domains disabled for the
interaction with phosphotyrosine residues. These mutants were
not affected for the interaction with hPIV3-C (data not shown).
This suggests that hPIV3-C either binds distinct regions of STAT1
and GRB2, or interacts with a region of the SH2 domain that does
not involve the phosphotyrosine binding site. Finally, our results
also show that full-length hPIV3-C is required to modulate IFN-
a/b and MAPK/ERK pathways since AA 90-195 that bind
STAT1 and GRB2 are unable to do so when expressed alone.
Full-length hPIV3-C was also required to observe a localization at
the cell membrane, suggesting a link with its activity. Interestingly,
the N-terminal 23 residues of Sendai virus C protein act as a
membrane targeting signal [56]. But the N-terminal residues of
hPIV3-C (AA 1-89) were unable to do so, and sequence analysis
did not show any conservation with the C protein of Sendai virus.
Thus, hPIV3-C tertiary structure is apparently required to target
this protein at the cell membrane. This specific localization could
both sequester STAT1 to prevent the stimulation of IFN-target
genes and contribute to the aggregation of GRB2-SOS complexes
to enhance MAPK/ERK signaling [57]. Altogether, this suggests
that hPIV3-C interaction with STAT1 and GRB2 represents a
potential target for the development of antiviral molecules against
hPIV3 and possibly other members of Respirovirus genus.
Materials and Methods
Plasmid DNA constructs
P-encoding sequence from hPIV3 wild-type strain (DF042505)
was amplified by RT-PCR (Titan One tube; Roche Applied
Science) from total RNA purified from infected cells (RNeasy kit;
Qiagen). Amplification was performed using the following hPIV3-P
specific primers flanked with Gateway cloning sites: 59-gggga-
caactttgtacaaaaaagttggcatgGAAAGCGATGCTAAAAACTATC-
AAA and 59-ggggacaactttgtacaagaaagttggttaTTGGCAATTATT-
GACATCTTCATTGAAC. PCR products were cloned using
TOPO TA Cloning kit (Invitrogen) into TOPO vector. A total of
21 clones were analyzed to establish the sequence of hPIV3-P
(GenBank ID: EU719627). Interestingly, 8 clones were not edited,
11 clones were edited by the addition of one G residue, and 2 clones
were edited by the addition of 5 G residues. One of the plasmids
containing the unedited sequence of hPIV3-P was selected and
subsequently used as a template to clone hPIV3-C.
DNA sequences encoding full-length hPIV3-C or fragments
corresponding to AA 1-89 or 90-195 were amplified by PCR from
p(hPIV3-P)-TOPO and cloned by in vitro recombination into
pDONR207 (Gateway system; Invitrogen) as previously described
[58]. Similarly, MV-C was amplified from p(+)MV323 that
contains the full genome of measles virus wild-type strain Ichinose
(kindly provided by Dr. K. Takeuchi, [59]). Nipah-C was
amplified from NiV-P plasmid (kindly provided by Dr. TF. Wild;
[60]). GRB2 coding sequence was amplified from the human
spleen cDNA library used to perform the yeast two-hybrid screen
(Invitrogen). The pDONR207 plasmid containing STAT1 was
previously described [58]. Viral or cellular coding sequences were
subsequently transferred by in vitro recombination from
pDONR207 into different Gateway-compatible destination vec-
tors (see below) following manufacturer’s recommendation (LR
cloning reaction, Invitrogen). To perform yeast two-hybrid
experiments, coding sequences were recombined into pPC86
(Invitrogen) to be expressed in fusion downstream of the activation
domain of Gal4 (Gal4-AD) or into pDEST32 to be expressed in
fusion downstream of the DNA binding domain of Gal4 (Gal4-
DB). In mammalian cells, GST-tag and 36FLAG-tag fusions were
achieved using pDEST27 (Invitrogen) or pCI-neo-36FLAG
vector, respectively [61]. We also used pCI-neo (Promega) and
pmCherry-C1 (Clontech) to express proteins without a tag or in
fusion downstream of Cherry, respectively. These two plasmids
were made Gateway-compatible using the Gateway vector
conversion system (Invitrogen).
Cell lines, viral infections and flow cytometry analysis
HEK-293T, Hela and Vero cells were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM; Gibco-Invitrogen) con-
taining 10% fetal bovine serum, penicillin, and streptomycin at
37uC and 5% CO2. A549 and BEAS-2B cells were maintained in
F-12K medium (Gibco-Invitrogen) containing 10% fetal bovine
serum, penicillin, and streptomycin at 37uC and 5% CO2. hPIV3
(strain C243) was amplified and titrated on Vero cells following
recommendations of ATCC (American Type Culture Collection).
Recombinant MV-EGFP virus used in Figure S2 has been
hPIV3-C Impact on IFN-a/b and EGF Pathways
PLoS Pathogens | www.plospathogens.org 12 September 2009 | Volume 5 | Issue 9 | e1000587previously described [62]. Infections were performed for 2 h at
37uC in Optimem (Gibco-Invitrogen). Later on, cells were washed
and incubated in fresh culture medium for 24 or 48 h. To detect
viral replication, cells were recovered and incubated in PBS-
paraformaldehyde 3.2% for 20 min. After extensive washing with
PBS, cells were permeabilized with PBS-Triton 0.05% for 15 min,
and then incubated with a monoclonal antibody specific to hPIV3-
HN (M02122321, Abcam). Cells were washed and incubated in
the presence of an anti-mouse Cy3-conjugated antibody (Jackson
Immunoresearch). After extensive washing, cellular immuno-
staining was analyzed using a FACSCalibur flow cytometer
(BD). When specified, cells were pre-treated with MEK1/2
specific inhibitor U0126 (20 mM final; Promega) for 2 h before,
during and after infection to study the impact on hPIV3 infection.
Co-affinity purification experiments
To perform co-affinity purification experiments, cloned ORFs
were transferred from pDONR207 to pDEST27 expression vector
(Invitrogen) to achieve GST fusion, and to pCI-neo-36FLAG
vector [61] for 36FLAG-fusion. Cell transfections were performed
using Lipofectamine 2000 (Invitrogen). Unless specified otherwise,
5610
5 HEK-293T cells were dispensed in each well of a 6-well
plate, and transfected 24 h later with 600 ng of each plasmid DNA
per well. Two days post transfection, HEK-293T cells were
washed in PBS, then resuspended in lysis buffer (0.5% Nonidet P-
40, 20 mM Tris–HCl at pH 8, 120 mM NaCl and 1 mM EDTA)
supplemented with Complete Protease Inhibitor Cocktail (Roche).
Cell lysates were incubated on ice for 20 min, and then clarified by
centrifugation at 14,0006g for 10 min. For pull-down analysis,
400 mg of protein extracts were incubated for 1 h at 4uC with
25 ml of glutathione-sepharose beads (Amersham Biosciences) to
purify GST-tagged proteins. Beads were then washed 3 times in
ice-cold lysis buffer and proteins were recovered by boiling in
denaturing loading buffer (Invitrogen).
Western blot analysis
Purified complexes and protein extracts were resolved by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) on 4–12%
NuPAGE Bis–Tris gels with MOPS running buffer (Invitrogen),
and transferred to a nitrocellulose membrane. Proteins were
detected using standard immunoblotting techniques. 36FLAG-
and GST-tagged proteins were detected with a mouse monoclonal
HRP-conjugated anti-36FLAG antibody (M2; Sigma-Aldrich)
and a rabbit polyclonal anti-GST antibody (Sigma-Aldrich),
respectively. Specific antibodies were used to detect endogenous
STAT1 (clone-1; BD Biosciences), GRB2 (clone-81; BD Biosci-
ences), phospho-ERK1/2 (clone-12D4; Upstate), ERK1/2 (CT;
Upstate), phospho-eIF4E (Ser209; Cell Signaling), eIF4E (Cell
Signaling), phospho-S6235-236 (Ser235/236; Cell Signaling), S6
(clone-54D2; Cell Signaling) and hPIV3-HN (M02122321;
Abcam). Secondary anti-mouse and anti-rabbit HRP-conjugated
antibodies were from GE-Healthcare. Densitometric analysis of
the gels was performed using a specific module of Photoshop CS3
Extended (Adobe Systems Inc.).
Yeast two-hybrid screening and gap-repair procedure
Our yeast two-hybrid protocols have been described in details
elsewhere [58]. Briefly, pDEST32 plasmid encoding Gal4-DB
fused to hPIV3-C was transformed in AH109 yeast strain
(Clontech), and used to screen by mating a human spleen cDNA
library cloned in the Gal4-AD pPC86 vector (Invitrogen) and
previously established in Y187 yeast strain (Clontech). Yeast cells
were plated on a selective medium lacking histidine and
supplemented with 10 mM 3-amino-triazole (3-AT; Sigma-
Aldrich) to select for interaction-dependent transactivation of
HIS3 reporter gene. AD-cDNAs from [His+] colonies were
amplified by PCR and sequenced to identify the host proteins
interacting with hPIV3-C.
The gap-repair procedure was used to map the minimal portion
of hPIV3-C interacting with STAT1 and GRB2. As previously
described [63], both forward and reverse PCR primers were
designed along the sequence of hPIV3-C and fused to specific tails
allowing yeast-based recombination in Gal4-DB two-hybrid
vector. Matrix combinations of forward and reverse primers were
used to amplify fragments of hPIV3-C by PCR. AH109 yeast cells
expressing AD-fused STAT1 or GRB2 were co-transformed with
5 mL of each PCR product in the presence 50 ng of linearized
pDEST32 vector to achieve recombinatorial cloning by gap-
repair. Fragments of hPIV3-C fused to Gal4-DB were then tested
for interaction with AD-STAT1 or AD-GRB2 by plating yeast
cells on selective medium lacking histidine and supplemented with
10 mM of 3-AT.
Luciferase reporter gene assay
HEK-293T, Hela or Vero cells were plated in 24-well plates
(2610
5 cells per well). One day later, cells were transfected with
either pISRE-Luc (0.3 mg/well; Stratagene) or pFA2-Elk1
(0.3 mg/well; Stratagene) and pGal4-UAS-Luc plasmids (0.3 mg/
well; provided by Dr. Y. Jacob) together with pRL-CMV reference
plasmid (0.03 mg/well; Promega). Cells were simultaneously co-
transfected with 0.3 mg/well of pCI-neo-36FLAG, pCI-neo or
pmCherryC1 expression vectors encoding viral proteins as
specified. 24 h after transfection, cells were stimulated with IFN-
b (Biosource) at 1000 IU/ml or starved for 6 h then stimulated
with EGF (Upstate) at 100 ng/ml. 24 h post transfection, cells
were lysed, and both firefly and Renilla luciferase activities in the
lysate were determined using the Dual-luciferase Reporter Assay
System (Promega). Reporter activity was calculated as the ratio of
firefly luciferase activity to reference Renilla luciferase activity, and
normalized so that positive control activity equals 100. When
indicated, cells were treated with U0126 (Promega) at 20 mM final
concentration upon EGF stimulation.
Subcellular localization of Cherry-tagged hPIV3-CFL,C 1-89
and C90-195
24-well plates containing coverslips were seeded with HEK-
293T cells (2610
5 cells per well). One day later, cells were
transfected with pmCherryC1 expression vector alone or encoding
hPIV3-CFL, hPIV3-C1-89 or hPIV3-C90-195. 36 h after transfec-
tion, cells were incubated with PBS-PFA 4% for 20 min at RT,
then treated with PBS-Triton 0.05% for 15 min at RT to
permeabilize the cells. Finally, cells were incubated for 10 min at
RT in a PBS-PFA 4% solution containing DAPI (49-6-Diamidino-
2-phenylindole) at 10 mg/ml. Preparations were mounted using
Fluoromount-G (Southernbiotech), and imaging performed using
a SP5 confocal miscroscope (Leica).
Supporting Information
Figure S1 ERK1/2 phosphorylation is enhanced by hPIV3
infection in A549 cells. A549 cells were infected with hPIV3
(MOI=3) and after 24 h, cells were starved for 12 h before
stimulation with 100 ng/ml of EGF. Phosphorylation of ERK1/2
was determined by western blot analysis at 10 min, 30 min and
2 h post stimulation. hPIV3 infection was confirmed by anti-
hPIV3 hemagglutinin-neuraminidase (hPIV3-HN) immunoblot-
ting.
Found at: doi:10.1371/journal.ppat.1000587.s001 (7.34 MB TIF)
hPIV3-C Impact on IFN-a/b and EGF Pathways
PLoS Pathogens | www.plospathogens.org 13 September 2009 | Volume 5 | Issue 9 | e1000587Figure S2 MEK1/2 inhibitor U0126 has no effect on MV
protein synthesis. HEK-293T cells were left untreated (A) or
treated with 20 mM of U0126 for 2 h (B). Then, cells were mock-
treated or infected with a recombinant MV strain expressing
EGFP (MOI=1) and cultured with or without U0126 (A and B,
respectively). 48 h after infection, EGFP expression was quantified
by flow cytometry analysis.
Found at: doi:10.1371/journal.ppat.1000587.s002 (7.34 MB TIF)
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